CristinaCusinMD
Psychiatry • Boston, MADirector of Translational Studies in Depression at Massachuseets General Hospital. Assistant Professor in Psychiatry at Harvard Medical School.
Dr. Cusin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
101 Nicolls Rd
Boston, MA 11794Phone+1 617-726-2066
Education & Training
Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 2006 - 2010
University of Milan Faculty of MedicineClass of 1997
Certifications & Licensure
MA State Medical License 2009 - 2026- American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression Start of enrollment: 2010 Nov 01
- Potential Use Of Brain Network Activation Analysis to Diagnose Major Depression Start of enrollment: 2012 Apr 01
- Neurobiological Bases of Placebo Response in Major Depressive Disorder Start of enrollment: 2012 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 305 citationsA Randomized Sham-Controlled Trial of Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Chronic Treatment-Resistant DepressionDarin D. Dougherty, Ali R. Rezai, Linda L. Carpenter, Robert H Howland, Mahendra T. Bhati
Biological Psychiatry. 2015-08-15 - 53 citationsSomatic therapies for treatment-resistant depression: ECT, TMS, VNS, DBSCristina Cusin, Darin D. Dougherty
Biology of Mood & Anxiety Disorders. 2012-08-17 - 53 citationsTranscranial Photobiomodulation for the Treatment of Major Depressive Disorder. The ELATED-2 Pilot TrialPaolo Cassano, Samuel R. Petrie, David Mischoulon, Cristina Cusin, Husam A. Katnani
Photomedicine and Laser Surgery. 2018-12-10
Journal Articles
- Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD)Sanjay J Mathew, Madhukar H Trivedi, Lee C Chang, Dan V Iosifescu, Manish K Jha, Maurizio Fava, Marlene P Freeman, Cristina Cusin, James Murrough, George I Papakostas,..., Nature
Press Mentions
Atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine TreatmentNovember 17th, 2022- Placebo Effect Large in Treatment-Resistant DepressionSeptember 30th, 2021
- Low Doses of Nitrous Oxide May Treat DepressionJune 26th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
